Interviews

Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.

Barbara O'Brien, MD, discusses the goals and results of a study investigating tucatinib, trastuzumab, and capecitabine for the treatment of leptomeningeal metastases in patients with HER2-positive breast cancer.

In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.

Elias Jabbour, MD, provides an overview of the significance of the FDA approval of ponatinib plus chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Denise Yardley, MD, discusses the takeaways and next steps of an analysis of the NATALEE trial investigating ribociclib in node-negative breast cancer.

Maya Dimitrova, MD, discusses areas of further research and unmet needs for patients with melanoma.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the potential benefits of antibody-drug conjugates in urothelial cancer while acknowledging the need for more education and experience among physicians to optimize their use.

In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.

In an interview, Aakash Desai, MD, MPH, discussed significant lung cancer treatment advancements that were highlighted at ASCO 2024.

Nazli Dizman, MD, discusses the importance of the 3 main clauses of the language of respect guidelines in renal cell carcinoma.

Mark Geyer, MD, and Yannis K. Valtis, MD, discussed real-world findings on the incidence, prevention, and management of tumor lysis syndrome in patients with CLL treated with venetoclax.

Jessica Paulus, ScD, discussed a study investigating real-world trends in lung cancer staging among community oncology practices.

Mark Geyer, MD, and Yannis K. Valtis, MD, delved into the background and findings from a study looking at clinical and laboratory tumor lysis syndrome in patients with CLL who were treated with venetoclax in the inpatient and outpatient settings.

Mina Lobbous, MD, MPH, discusses findings and implications fro a study investigating a new regimen for the treatment of brain metastases in patients with HER2-positive breast cancer.

Salma Jabbour, MD, discusses the implications of a 4-year follow-up of the KEYNOTE-799 study of pembrolizumab and chemoradiotherapy in stage III non–small cell lung cancer.

In an interview with Targeted Oncology, Francis P. Worden, MD, delved into the rationale behind the study and the implications of this research for patients with radioidine-refractory differentiated thyroid cancer.

David Spigel, MD, explains some of the unmet needs for patients with limited-stage small cell lung cancer and how they led to the initiation of the ADRIATIC trial.

Alexandra Gomez Arteaga, MD, discussed findings from a retrospective study comparing Orca-T with posttransplant cyclophosphamide graft-vs-host disease prophylaxis to assess outcomes in patients undergoing hematopoietic cell transplant.

Combining stereotactic radiosurgery with immunotherapy significantly improves overall survival in patients with renal cell carcinoma and brain metastasis.

In an interview, Cesar Augusto Perez, MD, delved into the findings from a phase 2 study evaluating petosemtamab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Paolo Ghia, MD, PhD, discusses the key takeaways from 5-year data follow-up data from the phase 2 CAPTIVATE trial of ibrutinib plus venetoclax for the treatment of patients with chronic lymphocytic leukemia and/or small lymphocytic lymphoma.

Neil Segal, MD, discussed findings from a phase 1/2 trial investigating REGN7075 in patients with solid tumors refractory to immunotherapy.

Vikram Narayan, MD, discussed the durable clinical activity observed with nadofaragene firadenovec in the CS-003 trial for patients with non-muscle invasive bladder cancer.

Ali Duffens, MD, discusses a study in which investigators assessed the mode of detection for breast cancer recurrence within an integrated health system by assessing the utility and outcomes of current surveillance guidelines recommended by the National Comprehensive Cancer Network.

Tanya Gupta, MD, highlighted the approved indications for antibody-drug conjugates in breast cancer, the efficacy data supporting their approvals, and ongoing studies to advance the space further.

Missak Haigentz, MD, discusses the impact of the results from the ADRIATIC study of durvalumab as consolidation treatment after concurrent chemoradiation for the treatment of patients with limited-stage small cell lung cancer.

Paula Rodríguez Otero, MD, PhD, discussed the deepening of response and minimal residual negativity during maintenance in the PERSEUS study for patients with multiple myeloma.

Mark A. Lewis, MD, discussed the growing excitement of using dostarlimab for the treatment of colorectal cancer and explored ways to maximize its potential.

Ravi Parikh, MD, MPP, discusses findings and implications of a study exploring algorithm-based palliative care recommendations.

Nikhil Khushalani, MD, discussed a phase 3 study investigating fianlimab plus cemiplimab vs nivolumab and relatlimab for the treatment of patients with advanced melanoma.